Aboriginal and Torres Strait Islander status may predict death in individuals with acute coronary syndrome.
The addition of the ezetimibe to simvastatin in patients with a recent acute coronary syndrome was not found to be associated with an increased incidence of patient-reported muscle complaints.
In the early rule-out of myocardial infarction, outcomes may be improved by accounting for the patient’s out-of-hospital experience, improving reassurance communication, and discussing future goals for cardiovascular health.
Impaired renal function was found to have negative long-term effects in individuals with acute coronary syndrome after percutaneous coronary intervention.
Several factors were found to be associated with the development of contrast-induced nephropathy after percutaneous coronary intervention in patients with ST-elevation myocardial infarction (STEMI) and non-ST-elevation acute coronary syndrome.
Researchers assessed the prevalence and incidence rate of cardiovascular morbidity in patients with inflammatory arthritis and determined whether the coexistence of multiple autoimmune disorders was associated with increased risk for cardiovascular disease.
Although mortality rates associated with cardiovascular disease have decreased significantly in high-income countries in recent decades, substantial challenges related to CVD treatment and outcomes persist in rural areas.
The electrocardiogram criteria for acute coronary syndrome were found to have very low diagnostic accuracy in patients presenting to the emergency department with chest pain.
The lowering of lipoprotein(a) with alirocumab was found to independently contribute to the reduction in major adverse cardiovascular events in patients with recent acute coronary syndrome.
In patients with acute coronary syndrome and obstructive sleep apnea, treatment with continuous positive airway pressure may not prevent the recurrence of major cardiovascular events.